Bromfenac
Antiinflammatory Agents, Non-Steroids
Sold as Yellox · PROLENSA · BROMSITE 0.075%
- Drug class
- Antiinflammatory Agents, Non-Steroids
- Availability
- Prescription only
- Routes
- Ophthalmic
- Markets covered
- 4
- Products on record
- 10
- FDA reports (12 mo)
- 117
Overview
Bromfenac is an active pharmaceutical ingredient in the Antiinflammatory Agents, Non-Steroids group (S01BC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 4 | August 1, 2025 |
| US United States | FDA | 2 | January 8, 2026 |
| EU European Union | EMA | 1 | April 8, 2026 |
| GB United Kingdom | MHRA | 3 | February 27, 2026 |
CACanada· Health Canada
4 products
Uses
AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS ................................................................................................... 3 WARNINGS AND PRECAUTIONS .................................................................................
4 ADVERSE REACTIONS ................................................................................................... 6 DRUG INTERACTIONS ...................................................................................................
8 DOSAGE AND ADMINISTRATION ............................................................................... 8 OVERDOSAGE ..................................................................................................................
9 ACTION AND CLINICAL PHARMACOLOGY ............................................................ 10 STORAGE AND STABILITY ......................................................................................... 11 SPECIAL HANDLING INSTRUCTIONS .......................................................................
USUnited States· FDA
2 products
Uses
09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction (1) .
How to take
EUEuropean Union· EMA
1 product
Uses
Yellox is indicated in adults for the treatment of postoperative ocular inflammation following cataract extraction .
How to take
GBUnited Kingdom· MHRA
3 products
3 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [4].
Drug interactions
Known interactions involving Bromfenac. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 267. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02439123 · revised August 1, 2025
- [2]FDA DailyMed · 08a0591e-6cb3-30… · revised October 26, 2023 [PDF]
- [3]European Medicines Agency · EMEA/H/C/001198 · revised April 8, 2026
- [4]MHRA (UK) · PLPI163781374 · revised January 30, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.